STOCK TITAN

Phibro Animal (PAHC) gains 5.1% passive stake from Barclays PLC

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Rhea-AI Filing Summary

Barclays PLC reported a passive ownership stake in Phibro Animal Health Corp-A common stock on a Schedule 13G. Barclays beneficially owns 1,042,888 shares, representing 5.10% of the class, with sole voting and sole dispositive power over all reported shares as of December 31, 2025.

Barclays states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Phibro Animal Health. Subsidiaries involved include Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd.

Positive

  • None.

Negative

  • None.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G



Barclays PLC
Signature:Ramya Rao
Name/Title:Director
Date:02/11/2026

FAQ

What did Barclays PLC disclose about Phibro Animal Health (PAHC)?

Barclays PLC disclosed a passive ownership position in Phibro Animal Health Corp-A common stock. It filed a Schedule 13G stating beneficial ownership of shares acquired and held in the ordinary course of business, without the purpose or effect of changing or influencing control of the company.

How many PAHC shares does Barclays PLC beneficially own?

Barclays PLC beneficially owns 1,042,888 shares of Phibro Animal Health Corp-A common stock. It reports sole voting power and sole dispositive power over the same 1,042,888 shares, indicating full authority to vote and dispose of this specific block of securities.

What percentage of Phibro Animal Health’s stock does Barclays hold?

Barclays PLC holds 5.10% of the outstanding common stock of Phibro Animal Health Corp-A. This percentage is based on its beneficial ownership of 1,042,888 shares, crossing the 5% threshold that requires public disclosure on a Schedule 13G filing.

Does Barclays intend to influence control of Phibro Animal Health (PAHC)?

Barclays states it does not intend to influence control of Phibro Animal Health. The filing certifies the securities were acquired and are held in the ordinary course of business, not for changing or influencing control or participating in transactions aimed at that purpose.

As of what date is Barclays’ ownership in PAHC reported?

Barclays’ ownership in Phibro Animal Health Corp-A is reported as of December 31, 2025. That date is the event requiring the Schedule 13G filing and anchors the disclosed 1,042,888 shares and 5.10% beneficial ownership percentage for regulatory reporting purposes.

Which Barclays entities are associated with the PAHC share ownership?

The filing identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as relevant subsidiaries. Barclays PLC reports beneficial ownership at the parent level, while these subsidiaries are referenced in connection with acquiring the securities and holding them on behalf of the group.
Phibro Animal

NASDAQ:PAHC

PAHC Rankings

PAHC Latest News

PAHC Latest SEC Filings

PAHC Stock Data

2.09B
20.48M
0.81%
105.02%
2.3%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
TEANECK